Next Article in Journal
Prevalence of IncFIB Plasmids Found among Salmonella enterica Serovar Schwarzengrund Isolates from Animal Sources in Taiwan Using Whole-Genome Sequencing
Next Article in Special Issue
Renal Thrombotic Microangiopathy in Concurrent COVID-19 Vaccination and Infection
Previous Article in Journal
Cystic Fibrosis Clinical Isolates of Aspergillus fumigatus Induce Similar Muco-inflammatory Responses in Primary Airway Epithelial Cells
Previous Article in Special Issue
Molecular Epidemiology of Sapovirus in Children Living in the Northwest Amazon Region
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 10
Issue 8
10.3390/pathogens10081021
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Anti-Inflammatory Properties of Plasma from Children with Short Bowel Syndrome

by
Irshad Ahmed Hajam
1,
Farhana Ali
2,3,
Jocelyn Young
2,3,
Mary Abigail Garcia
2,3,
Christopher Cannavino
1,3,
Nanda Ramchandar
1,3,* and
George Y. Liu
1,3,*
1
Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, CA 92123, USA
2
Department of Pediatrics, Division of Gastroenterology, University of California, San Diego, CA 92123, USA
3
Rady Children’s Hospital, San Diego, CA 92123, USA
*
Authors to whom correspondence should be addressed.
Pathogens 2021, 10(8), 1021; https://doi.org/10.3390/pathogens10081021
Submission received: 21 July 2021 / Revised: 7 August 2021 / Accepted: 11 August 2021 / Published: 13 August 2021
(This article belongs to the Special Issue Advances in Human Pathogens Infections)
Browse Figures
Versions Notes

Abstract

:
Sepsis, resulting from a dysregulated host immune response to invading pathogens, is the leading cause of mortality in critically ill patients worldwide. Immunomodulatory treatment for sepsis is currently lacking. Children with short bowel syndrome (SBS) may present with less severe symptoms during gram-negative bacteremia. We, therefore, tested the hypothesis that plasma from children with SBS could confer protection against Escherichia coli sepsis. We showed that SBS plasma at 5% and 10% concentrations significantly (p < 0.05) inhibited the production of both TNF-α and IL-6 induced by either E. coli- or LPS-stimulated host cells when compared to plasma from healthy controls. Furthermore, mice treated intravenously with select plasma samples from SBS or healthy subjects had reduced proinflammatory cytokine levels in plasma and a significant survival advantage after E. coli infection. However, SBS plasma was not more protective than the plasma of healthy subjects, suggesting that children with SBS have other immunomodulatory mechanisms, in addition to neutralizing antibodies, to alleviate their symptoms during gram-negative sepsis.

1. Introduction

Short bowel syndrome (SBS) is a malabsorptive state that classically results from surgical resection of the small intestine for various reasons, including congenital anomalies of the gastrointestinal tract or acquired traumatic injuries such as necrotizing enterocolitis in infants [1,2,3]. Owing to the considerable intestinal loss and resultant inadequate absorption of fluids, electrolytes, and nutrients, parenteral nutrition (PN) is the gold standard for treatment to support growth and nutrition and is an essential life-saving intervention for most patients severely affected by SBS [4,5,6,7]. Although PN has dramatically improved the survival of SBS patients [7,8], its use negatively impacts gut barrier functions and mucosal immunity. PN-dependent SBS patients have been reported to have increased intestinal permeability, short bowel bacterial overgrowth (SBBO) and enteritis, reduced microbiome diversity, catheter-related bacterial sepsis, and gastrointestinal mucosal atrophy [7,9,10,11,12,13].
A critical function of the gut mucosal epithelium is to prevent bacterial translocation, a phenomenon in which gut resident pathogenic microbes and their components traverse to the underlying tissues via transcellular or paracellular pathways [14,15]. Animal models [16] and limited human studies [17,18,19,20] support the role of PN as an inducer of local or systemic inflammation concomitant with the gut barrier dysfunction and bacterial translocation. A study by Ziegler et al. showed that patients with SBS are serially and intermittently exposed to increased systemic levels of bacterial products, including flagellin and lipopolysaccharide (LPS), and serum antibody titers against these bacterial products are readily detectable [21]. LPS, an endotoxin, is recognized as the most potent microbial mediator involved in the pathogenesis of sepsis [22], which is a dysregulated host immune response to infections, leading to tissue damage and multiple organ failure [23]. In mice, the systemic inoculation of bacteria [24,25] or LPS [26] potently activates a lethal array of inflammatory mediators and results in a sepsis-like syndrome or death. Our institutional experience, in accordance with other reports describing children with SBS and other cohorts of bacteremic children, has been that children with SBS have high rates of bloodstream infections with sepsis-causing gram-negative (GN) bacterial species [27,28,29], yet some have clinically shown only modest symptoms with GN infections. Furthermore, both LPS and flagellin, which cause sepsis in otherwise healthy populations, have been detected in patients with SBS [30]. The phenomenon of tolerance to a sepsis-like situation in SBS patients could be attributable to either the presence of microbe-specific antibodies or impairments to T cell responses or, potentially, a combination of both. Limited human studies have shown that SBS patients have impaired T cell responses and poorly respond to antigenic stimulation [31], while competent T cells can increase sepsis morbidity and tissue injury [32]. Considering that SBS subjects are frequently exposed to systemic GN bacteria, we hypothesized that these children may have a robust anti-GN bacterial humoral response to shield them from the sepsis syndrome. Accordingly, we sought to determine whether plasma from SBS subjects would prevent Escherichia coli sepsis in a murine model. Such studies would explain the relative SBS subjects’ relative tolerance to GN sepsis and could lead to the development of novel interventions against GN sepsis and septic shock.
We used a well-characterized murine model of E. coli sepsis to test the protective effect of plasma from children with SBS against sepsis-induced cytokine inflammation and mortality. Our data demonstrate that SBS, as well as healthy plasma therapy in mice challenged with a lethal dose of E. coli, improved host survival. In vivo protection is consistent with the finding of plasma inhibition of cellular immune responses induced by LPS and multiple E. coli strains in vitro.

2. Results

2.1. Anti-Inflammatory Effect of Plasma from SBS and Healthy Subjects In Vitro

The effect of plasma from SBS and healthy subjects on LPS- and E. coli-mediated cellular responses was evaluated in splenocyte stimulation assays. Notably, the SBS plasma samples were derived from children, and plasma from healthy controls (HC) were from adults. Splenocytes from CD1 mice were incubated with plasma from SBS or HC, along with either LPS or E. coli. The production of TNF-α and IL-6 in culture supernatant was measured by ELISA. The results showed that the inhibition of TNF-α and IL-6 production varied depending on the cytokine being examined, the concentration of plasma sample used to neutralize the LPS (Figure 1), and the E. coli strain used for the stimulation of cells (Figure 2). All plasma samples from subjects with SBS at both 5% (Figure 1A,B) and 10% concentrations (Figure 1C,D) significantly (p < 0.05) inhibited the ability of LPS to stimulate TNF-α (~1.4–1.6 fold) and IL-6 (1.3–1.5 fold) secretion compared to the HC, which exhibited comparable cytokine levels to cells stimulated by LPS alone (Supplementary Figure S1A–D). At a 20% concentration, however, plasma from either SBS or HC markedly suppressed TNF-α and IL-6 secretion by splenocytes stimulated with LPS. Compared to cells stimulated with LPS alone, TNF-α levels were 14.5- and 8.3-fold lower with the plasma samples from SBS and the HC subjects, respectively (Figure 1E). The IL-6 levels were equally inhibited by SBS and HC samples, and were ~14-fold lower than the cells stimulated with LPS alone (Figure 1F). As a baseline control, we measured IL-6 and TNF-α levels in plasma samples by ELISA. Both IL-6 and TNF-α were undetectable in SBS and HC plasma samples (data not shown). Overall, our results indicate that the plasma from either SBS or healthy subjects has the ability to neutralize the proinflammatory activities of LPS, though plasma from SBS subjects is relatively more effective than plasma from HC subjects.
Next, we tested the effect of plasma from SBS and HC subjects on the inflammation induced by E. coli co-incubated with mouse splenocytes in vitro. We showed that both SBS and HC plasma samples significantly (p < 0.05) inhibited TNF-α production induced by the respective E. coli strains (Figure S2A–C), although a more profound inhibition of TNF-α production was observed with the plasma samples from subjects with SBS (Figure 2A–C). SBS plasma was 2–3-fold more effective at suppressing TNF-α in the culture supernatant compared to plasma from HC. Furthermore, the TNF-α inhibition was similar across all the tested E. coli strains, with the highest inhibition observed with the SBS2 plasma sample (Figure S2B,C). For IL-6, HC plasma samples had no significant effect on IL-6 production induced by E. coli strains (Figure S2D–F), except for controls 3 and 4, which elicited a significant inhibition of IL-6 production against E. coli O86:B1 strain (Figure S2F). Irrespective of the E. coli strain, all the plasma samples from SBS subjects significantly (p < 0.05) inhibited the production of IL-6 when compared to splenocytes stimulated by E. coli alone (Figure S2D–F). Compared to HC samples, SBS plasma samples significantly inhibited IL-6 production only against the K1 strain (Figure 2E), while no significant difference was found for other E. coli strains (Figure 2D,F). Overall, our data suggest that plasma from the SBS subjects is more effective at neutralizing E. coli-induced pro-inflammatory cytokine responses in vitro.

2.2. Effect of Plasma from SBS and HC Subjects on Pro-Inflammatory Cytokine Levels in an E. coli Sepsis Murine Model

To assess the effect of SBS plasma on sepsis-mediated proinflammatory cytokine responses, we treated mice intravenously with PBS, plasma from HC, or plasma from SBS subjects; then, the mice were injected with an LD100 dose E. coli (5 × 107 CFU) administered intraperitoneally. The mice that received PBS alone showed a robust induction of TNF-α (Figure 3A) and IL-6 (Figure 3B) production, while the treatment of mice with HC1, HC4, SBS1 or SBS3 led to substantial inhibition of these cytokines (Figure 3A,B). Although no significant difference was observed between SBS4 and PBS treatments, there was a trend towards inhibition of TNF-alpha, although this was not found in the IL-6 in SBS4 treatment group.
We also evaluated the effect of SBS and HC plasma samples in a model of lower acuity E. coli sepsis. Mice (n = 3–4) pretreated with either SBS or HC plasma samples were challenged with a sub-lethal dose of E. coli (1.5 × 107 CFU), then sacrificed at 24 h for analysis of IL-6, TNF-α and IL-1 β in the mouse plasma and spleen (Figure S3). In plasma, we could detect only IL-6, which was statistically non-significant among treatment groups (Figure S3A). In contrast, all three measured cytokines were detected in spleen homogenates. The levels of TNF-α (Figure S3B) and IL-6 (Figure S3D) were non-significant among treatment groups, except for the HC4 treatment group, which showed significantly (p < 0.05) lower IL-6 levels compared to the mice treated with PBS alone. Although the levels of IL-1β did not reach statistical significance among treatment groups, mice treated with HC1, HC4, SBS1, SBS2, and SBS3 showed a trend of inhibition (p = 0.057) compared to the mice that received PBS alone (Figure S3D). We also looked at CFUs in spleens 24 h post-challenge (Figure S3G). Although CFUs were statistically non-significant among treatment groups, there was also a trend toward lower CFUs in mice treated with either HC or SBS plasma samples. Overall, our data indicate that SBS and HC plasma have potential anti-inflammatory properties in vivo.

2.3. Effect of Plasma from SBS and HC Subjects on Mortality Induced by E. coli in a Murine Sepsis Model

To investigate whether plasma from SBS subjects can prevent sepsis-induced mortality, we treated mice with PBS, HC plasma, or SBS plasma followed by infection with a lethal dose of E. coli (5 × 107 CFU). Treatment with PBS alone resulted in 100% mortality on day 4, while treatment with plasma from either SBS (Figure 4A) or HC (Figure 4B) provided a marked survival benefit against lethal sepsis. Mice that were treated with SBS2 or SBS3 plasma showed 50% (3 out of 6) survival, while SBS1- and SBS4-plasma-treated mice had only 16.6% (1 out of 6) and 0% (6 out of 6) protection, respectively. Excepting the HC4 treatment group, which led to a 60% (3 of 5) survival rate, treatment with all other HC plasma samples showed a 20% (1 out of 5) protection rate. We also measured the body weight of mice following the LD100 E. coli challenge. The results show that mice treated with SBS1, SBS2, or SBS3 initially resisted any changes in body weight until day 3, while all other treatment groups, except HC4, showed a substantial loss in body weight from day 1 post-challenge (Figure 4C). Treatment with HC4 plasma did not affect the body weight of mice following the LD100 E. coli challenge. Overall, our data indicate that plasma from both SBS and HC subjects can have a mitigating effect against sepsis-induced mortality.

3. Discussion

Despite the substantial progress made in the understanding of the pathophysiology of sepsis, there are no effective immunomodulatory therapies available to date for treatment of GN sepsis. Many previous efforts to control the overwhelming inflammation related to sepsis have been met with failure [33]. The present study used a well-established model of GN E. coli sepsis to investigate whether plasma from SBS patients could mediate protection against sepsis-induced mortality in mice. The relative lack of clinically severe symptoms exhibited by SBS patients with GN sepsis provided the rationale underlying our hypothesis. SBS plasma inhibited the secretion of proinflammatory cytokines induced by LPS or multiple clinical E. coli strains in vitro. Intravenous treatment with selected SBS and control plasma also inhibited sepsis-associated cytokines, and reduced mortality in mice challenged with a reproducibly lethal dose of E. coli.
Polyclonal intravenous immunoglobulins (IVIG), a pooled preparation of IgG antibodies, are frequently used in severely ill septic patients, due to their unique functions in eradicating pathogens and neutralizing toxins [34,35]. However, multiple IVIG clinical trials demonstrated inconsistent beneficial effects, possibly accounted for by the use of preparations from heterogeneous populations, lacking in specific protective immunity against sepsis-causing bacteria. More recent data have supported the additional benefits of using IVIG preparations specific to the causative agent related to sepsis [36,37]. Due to the frequent bacterial translocation with enteric GN pathogens, we hypothesized that SBS patients would have robust neutralizing antibodies to GN bacteria. Consistent with previous reports [27,38], we found a serum IgG antibody for LPS and E. coli strains in SBS as well as in healthy subjects (data not shown), suggesting that systemic B cell responses to gut-derived microbial antigens commonly occur irrespective of the state of the host. Plasma samples from SBS subjects have more profound inhibitory effects on LPS- and E. coli-mediated IL-6 and TNF-α production by host cells when compared to samples from HC subjects in vitro. We observed lower levels of pro-inflammatory cytokines in mice treated with select plasma samples from either SBS or HC subjects, which may explain the protection against sepsis-induced mortality. We demonstrated that mice receiving SBS plasma therapy survived longer than PBS-treated mice and that two of the four SBS plasma samples resulted in 50% protection against sepsis-induced mortality. However, the benefits against sepsis-induced mortality were also observed in mice treated with plasma samples from the HC subjects. Notably, among all the plasma-treated groups, the HC4 treatment group showed the lowest levels of cytokine inflammation and the most protection against sepsis-induced mortality, suggesting that some healthy subjects could elicit potent antibody responses against the gut microbes. This finding was in agreement with the previous report, which demonstrated that commensal-specific IgG antibodies mediate efficient protection against the translocated symbionts or the invasive enteric pathogens in systemic infection [38]. The variations in protection induced by different plasma samples are likely multi-factorial for various reasons, including age, microbiome diversity, comorbidities, and genetic polymorphisms; all of these could contribute to the development of B cell responses, unique to an individual. Therefore, some individuals might generate highly protective antibodies, which are more capable of performing multiple functions, including phagocytosis, activation of the complement system, efficient neutralization of endotoxins, and activation of various innate immune cells, which might explain why in vivo protection varied among treatment groups. Moreover, the heterogeneous presentations of sepsis, characterized by highly complex and individualized immune responses, suggest that there will not be a single “silver bullet” that can effectively treat sepsis. A study by Speer et al. showed that the addition of pentoxifylline, a phosphodiesterase inhibitor, to antibiotics in murine E. coli sepsis promoted anti-inflammatory milieu in plasma and organs without promoting bacterial growth [39], indicating that adjunctive therapies might be beneficial to manage sepsis-induced inflammation and mortality. The above study supports our proposal that plasma samples from SBS subjects with antibodies specific to sepsis-related microbes might be a safe and effective anti-inflammatory adjunctive therapy to manage sepsis-induced inflammation and mortality.
This study set out to test whether plasma from SBS subjects would provide robust protection against GN sepsis compared to plasma from healthy subjects. Unexpectedly, we did not see a relative lack of clinically significant symptoms in mice that received SBS plasma compared to mice that received healthy human plasma. It is possible that this lack of difference is due to the age of the plasma donors—older healthy plasma donors versus pediatric SBS plasma donors. Additionally, the results may have been affected by the heterogeneity within the SBS population, as subjects differed in the extent of PN dependence, number of known central line infections, time since last central line infection, isolated organisms, and time since last antibiotic exposure. This is further complicated by the inadequate methods of assessing intestinal health in subjects with SBS [40,41]. GN sepsis in mice was induced with a supraphysiologic inoculum of E. coli not seen in human disease and, therefore, may not accurately reflect the LPS-neutralizing antibody activities noted in the in vitro splenocyte assay. We favor the explanation that immune cells in SBS subjects, other than antibodies, conferred additional protection against overwhelming inflammation during GN sepsis. For example, limited human studies have shown that gut resection negatively impacts systemic immune responses, especially T cell responses [31,42]. Such studies have shown that patients with SBS have dysfunctional T cell responses, characterized by reduced cytokine and proliferative responses upon antigenic stimulation. Furthermore, regulatory T cells (Tregs) are found in higher proportions in SBS patients than in match-controlled subjects, indicating that SBS patients may have multiple immune evasion mechanisms to prevent a sepsis-like situation. Additional potential innate immune adaptation, for example, M1 to M2 conversion, has not been well studied. Understanding the fundamental biological processes governing the phenomenon of immune tolerance in SBS patients, including the interplay between the host and microbiome, would lead to a better understanding of the mechanisms underlying lack of SBS patient reactivity to GN sepsis, and could provide insight into the development of novel therapies against sepsis and septic shock, some of which may include either targeted therapeutic approaches by immunomodulation, alterations of the microbiome with probiotics, or a combination of both [43,44,45,46].

4. Conclusions

We show that intravenous treatment with plasma from SBS as well as healthy subjects can improve host survival in mice challenged with a lethal dose of E. coli, although without a significant difference in efficacy between SBS and healthy plasma. Future studies should evaluate plasma and PBMC samples from a large cohort of SBS patients, which could provide information on a more effective management of GN sepsis, beyond the use of antibiotics. To the extent that sepsis-induced organ damage and mortality is driven by proinflammatory cytokines, our study warrants an investigation into SBS plasma samples in combination with current standard sepsis therapies to determine if sepsis-induced inflammation and mortality could be improved.

5. Materials and Methods

5.1. Bacterial Strains and Culture Conditions

Clinical E. coli strains, including ATCC 25922, K1 RS218, and O86:B1, were used in this study. The E. coli strains were grown in 5 mL of Luria Bertani (LB) broth with agitation to a log phase (OD600nm = 0.65–0.7) at 37 °C. The bacterial culture was centrifuged at 2400× g for 5 min and the pellet was washed twice with sterile phosphate-buffered saline (PBS; pH = 7.40). The bacterial pellet was finally resuspended in PBS to the desired colony-forming units (CFU) for further use.

5.2. In Vitro Studies with Plasma from SBS Subjects

CD1 mouse splenocytes (n = 3) were used to study the effect of plasma from SBS and HC subjects on the cellular immune responses mediated by LPS and E. coli in vitro. Subjects were recruited at outpatient pediatric gastroenterology clinic visits. Inclusion criteria included children aged 5–18 years with anatomic SBS and central line access for chronic PN use. Exclusion criteria included presence of fever within 30 days prior or antibiotic administration within 7 days prior to the visit. The demographics and characteristics of the SBS subjects are provided in Table 1. Adults aged 18 years or older with no underlying acute or chronic illness were utilized as control subjects; again, those who had fever within 30 days or received antibiotics within 7 days prior to recruitment were excluded.
LPS (1 µg/mL) or E. coli (1 × 108 CFU/mL) was incubated with 5%, 10%, or 20% of plasma from either HC or SBS subjects at room temperature, under continuous shaking for 30 min. The mixture containing 250 ng of LPS or 1 × 106 CFU of E. coli was then applied to the splenocytes (1 × 106 cells), followed by incubation of the cells at 37 °C under 5% CO2. Cells stimulated with either LPS alone or with the E. coli strain alone were used as positive controls and media-treated cells were used as the negative controls. The splenocytes were plated in a Falcon® 96-well tissue culture plate (Catalog no. #353072, corning incorporated, USA) and cultured in complete RPMI medium (Gibco, ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum and 1x penicillin–streptomycin antibiotics solution (Catalog#P4333, Sigma-Aldrich, St. Louis, MO, USA). After 24 h incubation, the cells were centrifuged at 450× g and the culture supernatant was collected for analysis of the proinflammatory cytokines, including IL-6 and TNF-α, by a solid-phase sandwich enzyme-linked immunosorbent assay (ELISA; Biolegend, San Diego, CA, USA).

5.3. In Vivo Efficacy of Plasma from SBS Subjects on Sepsis-Induced Mortality

All animal studies were approved under the guidelines of the University of California San Diego (UCSD) Institutional Animal Care and Use Committee. Outbred 6–8-week-old female CD1 mice (The Charles River Laboratory) were housed in an animal facility at UCSD with a standard of care as per federal, state, local, and NIH guidelines.
Before SBS plasma samples were tested, the lethal dose (LD) was determined in groups of 4 mice inoculated with different CFU of E. coli ATCC 25922 strains, suspended intraperitoneally in 200 μL of 1×PBS (Figure S4). The inoculum that causes 100% mortality was defined as LD100 and used to study the efficacy of plasma samples on the survival of mice, following E. coli challenge. To evaluate the effect of plasma samples from SBS and HC on cytokine inflammation, mice were divided into 8 groups (n = 6) and administered retro-orbitally with 100 μL of plasma from either SBS or healthy subjects (n = 4). Mice that received PBS alone (n = 5) served as a positive control for sepsis-induced mortality. The retroorbital injection was performed under Isoflurane (Fluriso, Vet One) anesthesia. Sixteen hours after treatment with plasma samples, mice were challenged with LD100 E. coli intraperitoneally and bled 22 h later for quantification of proinflammatory cytokines, including TNF-α and IL-6, in mouse plasma obtained from the heparinized blood, spun at 10000 rpm for 10 min. To evaluate the effect on survival, the mice were pretreated as previously discussed, and then infected and monitored for survival over 6 days.
To further evaluate the effect of HC and SBS plasma samples on the induction of proinflammatory cytokine responses in a less severe sepsis model, mice were treated retro-orbitally with 100 µL of either HC or SBS plasma, followed by challenge with an intraperitoneal sub-lethal dose of E. coli (1.5 × 107 CFU). Twenty-four hours later, plasma and spleens were collected for cytokine estimation and CFU enumeration. For CFU enumeration, spleens were homogenized in 200 µL of sterile PBS in microcentrifuge tubes, and then serially diluted with PBS (from 10−1 to10−4) and plated onto agar plates. After 24 h of culture, bacterial colonies were counted.

5.4. Cytokine ELISA

IL-6, IL-1β and TNF-α cytokine levels were measured by a solid-phase sandwich ELISA using commercially available cytokine ELISA kits (Biolegend, San Diego, CA, USA). The assay was performed in duplicate or triplicate, as per manufacturer’s instructions. The culture supernatants, blood plasma samples, or splenic homogenates were diluted 1:1 with coating buffer (1%BSA + 1xPBS-Tween20) and used in the assay, along with the known concentration of cytokine standards (provided with the kits) in each ELISA plate. The plates were developed and read at optical density (OD) of 450 nm in a multimode microplate reader (PerkinElmer, Waltham, MA, USA). The standard curve generated from the OD of cytokine standards was used to determine cytokine levels in the samples.

5.5. Statistical Analysis

GraphPad prism version 8 was used to analyze the data. Cytokine data are presented as a median, and a non-parametric Mann–Whitney test was used to analyze the significant difference between treatment groups. Differences in survival (%) between treatment groups were compared by the use of a log-rank (Mantel–Cox) Chi square test. p values of <0.05 were considered significant.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/pathogens10081021/s1, Figure S1: LPS neutralization in vitro. E. coli LPS incubated with various concentrations of plasma from subjects with SBS or HC, including 5% (A&B) and 10% (C&D), was applied to mouse splenocytes cultured in RPMI media at 37 °C. TNF-α and IL-6 from the culture supernatants were quantified by a solid-phase sandwich ELISA performed in duplicate or triplicate wells. Data are presented as mean ± SD, and a parametric unpaired T-test was applied to analyze the statistical significance. * p < 0.05. SBS: short bowel syndrome, HC: healthy controls. Figure S2: Anti-inflammatory effect of plasma from SBS or HC subjects in E. coli-stimulated splenocyte cultures. E. coli strains ATCC 25922 (A&D), K1 RS218 (B&E), and O86:B1 (C&F) were incubated with either plasma from SBS or HC and applied to the mouse splenocytes cultured at 37 °C. TNF-α and IL-6 pro-inflammatory cytokines were quantified in the culture supernatant by a solid-phase sandwich ELISA performed either in duplicate or triplicate wells. Data are presented as mean ± SD, and a parametric unpaired T-test was applied to analyze the statistical significance. *p < 0.05. SBS: short bowel syndrome, HC: healthy controls. Figure S3: Anti-inflammatory effect of plasma from SBS and HC subjects on sub-lethal E. coli sepsis. Mice (n = 3–4) administered intravenously with PBS, SBS plasma or HC plasma were intraperitoneally challenged 16 h later with 1.5 × 107 CFU of E. coli ATCC 25922 strain. Blood from each mouse was collected 24 h later, and TNF-α, IL-1β, and IL-6 levels in plasma and spleen were determined by ELISA. Data are presented as median, with each datapoint representing one mouse. Non-parametric Mann–Whitney T-test was applied to analyze the statistical significance. *p < 0.05, **< 0.001. SBS: short bowel syndrome, HC: healthy controls. Figure S4: LD100 evaluation for E. coli ATCC 25922 strain in a peritonitis-induced sepsis model. Groups of 4 mice were injected with different CFUs of an E. coli strain 25922, suspended intraperitoneally in 200 µL of 1xPBS. The mice were monitored over seven days, and the number of deaths in each group was recorded daily. The survival data were evaluated using a log-rank Mantel–Cox test. dpi; days post-infection. p < 0.001.

Author Contributions

Conceptualization, F.A., N.R., G.Y.L., J.Y., C.C. and M.A.G.; Enrollment of SG subjects and controls, F.A., J.Y., M.A.G.; Methodology, I.A.H.; Validation, I.A.H.; Formal Analysis, I.A.H.; Investigation, I.A.H.; Resources, G.Y.L. and N.R.; Data Curation, I.A.H.; Writing—Original Draft Preparation, I.A.H.; Writing—Review and Editing, C.C., J.Y., F.A., G.Y.L., M.A.G., N.R.; Supervision, G.Y.L.; Funding Acquisition, G.Y.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by internal funding from UCSD and by a NIH grant T32DK007202 to JY.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of University of California San Diego (Human Research Protection Program project #201235X; approved 8/12/2020).

Informed Consent Statement

Informed consent was obtained from the guardians of all subjects involved in the study.

Data Availability Statement

HYPERLINK “C:\\Users\\nramchandar\\Downloads\\Deidentified” Deidentified data is available from the authors upon reasonable request.

Acknowledgments

We thank Victor Nizet for gift of E. coli strains used in this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vanderhoof, J.A.; Langnas, A.N.; Pinch, L.W.; Thompson, J.S.; Kaufman, S.S. Short bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 1992, 14, 359–370. [Google Scholar] [CrossRef]
  2. Wales, P.W.; De Silva, N.; Kim, J.H.; Lecce, L.; Sandhu, A.; Moore, A.M. Neonatal short bowel syndrome: A cohort study. J. Pediatr. Surg. 2005, 40, 755–762. [Google Scholar] [CrossRef]
  3. Goulet, O.; Ruemmele, F. Causes and management of intestinal failure in children. Gastroenterology 2006, 130, S16–S28. [Google Scholar] [CrossRef]
  4. Vlug, L.E.; Nagelkerke, S.C.J.; Jonkers-Schuitema, C.F.; Rings, E.H.H.M.; Tabbers, M.M. The role of a nutrition support team in the management of intestinal failure patients. Nutrients 2020, 12, 172. [Google Scholar] [CrossRef] [Green Version]
  5. Wilmore, D.W.; Groff, D.B.; Bishop, H.C.; Dudrick, S.J. Total parenteral nutrition in infants with catastrophic gastrointestinal anomalies. J. Pediatr. Surg. 1969, 4, 181–189. [Google Scholar] [CrossRef]
  6. Buchman, A.L.; Moukarzel, A.A.; Bhuta, S.; Belle, M.; Ament, M.E.; Eckhert, C.D.; Hollander, D.; Gornbein, J.; Kopple, J.D.; Vijayaroghavan, S.R. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. J. Parenter. Enter. Nutr. 1995, 19, 453–460. [Google Scholar] [CrossRef] [PubMed]
  7. Duran, B. The effects of long-term total parenteral nutrition on gut mucosal immunity in children with short bowel syndrome: A systematic review. BMC Nurs. 2005, 4, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Thakur, A.; Chiu, C.; Quiros-Tejeira, R.E.; Reyen, L.; Ament, M.; Atkinson, J.B. Fonkalsrud EW. Morbidity and mortality of short-bowel syndrome in infants with abdominal wall defects. Am. Surg. 2002, 68, 75–79. [Google Scholar] [PubMed]
  9. Zeichner ID, S.L.; Mongodin, E.F.; Hittle, L.; Huang, S.-H.; Torres, C. The bacterial communities of the small intestine and stool in children with short bowel syndrome. PLoS ONE 2019, 14, e0215351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Alverdy, J.C.; Aoys, E.; Moss, G.S. Total parenteral nutrition promotes bacterial translocation from the gut. Surgery 1988, 104, 185–190. [Google Scholar] [PubMed]
  11. O’keefe, S.J.D.; Burnes, J.U.; Thompson, R.L. Recurrent Sepsis in Home Parenteral Nutrition Patients: An Analysis of Risk Factors. J. Parenter. Enter. Nutr. 1994, 18, 256–263. [Google Scholar] [CrossRef] [PubMed]
  12. Alverdy, J.; Chi, H.S.; Sheldon, G.F. The effect of parenteral nutrition on gastrointestinal immunity. The importance of enteral stimulation. Ann. Surg. 1985, 202, 681–684. [Google Scholar] [CrossRef]
  13. D’Antiga, L.; Dhawan, A.; Davenport, M.; Mieli-Vergani, G.; Bjarnason, I. Intestinal absorption and permeability in paediatric short-bowel syndrome: A pilot study. J. Pediatr. Gastroenterol. Nutr. 1999, 29, 588–593. [Google Scholar] [CrossRef] [PubMed]
  14. McAndrew, H.F.; Lloyd, D.A.; Rintala, R.; Van Saene, H.K.F. The effects of intravenous epidermal growth factor on bacterial translocation and central venons catheter infection in the rat total parenteral nutrition model. Pediatr. Surg. Int. 2000, 16, 169–173. [Google Scholar] [CrossRef] [PubMed]
  15. Bruewer, M.; Luegering, A.; Kucharzik, T.; Parkos, C.A.; Madara, J.L.; Hopkins, A.M.; Nusrat, A. Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis-Independent Mechanisms. J. Immunol. 2003, 171, 6164–6172. [Google Scholar] [CrossRef] [Green Version]
  16. Ziegler, T.R.; Evans, M.E.; Fernández-Estívariz, C.; Jones, D.P. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu. Rev. Nutr. 2003, 23, 229–261. [Google Scholar] [CrossRef]
  17. Briet, F.; Flourié, B.; Achour, L.; Maurel, M.; Rambaud, J.C.; Messing, B. Bacterial adaptation in patients with short bowel and colon in continuity. Gastroenterology 1995, 109, 1446–1453. [Google Scholar] [CrossRef]
  18. Buchman, A.L.; Moukarzel, A.; Goodson, B.; Herzog, F.; Pollack, P.; Reyen, L.; Alvarez, M.; Ament, M.E.; Gornbein, J. Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. J. Parenter. Enter. Nutr. 1994, 18, 297–302. [Google Scholar] [CrossRef]
  19. Ziegler, T.R.; Smith, R.J.; O’dwyer, S.T.; Demling, R.H.; Wilmore, D. Increased Intestinal Permeability Associated With Infection in Burn Patients. Arch. Surg. 1988, 123, 1313–1319. [Google Scholar] [CrossRef]
  20. O’Boyle, C.J.; MacFie, J.; Mitchell, C.J.; Johnstone, D.; Sagar, P.M.; Sedman, P.C. Microbiology of bacterial translocation in humans. Gut 1998, 42, 29–35. [Google Scholar] [CrossRef]
  21. Ziegler, T.R.; Luo, M.; Estívariz, C.F.; Moore, D.A.; Sitaraman, S.V.; Hao, L.; Bazargan, N.; Klapproth, J.M.; Tian, J.; Galloway, J.R.; et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294, R402. [Google Scholar] [CrossRef]
  22. Opal, S.M. Endotoxins and other sepsis triggers. Contrib. Nephrol. 2010, 167, 14–24. [Google Scholar] [CrossRef]
  23. Angus, D.C.; van der Poll, T. Severe Sepsis and Septic Shock. N. Engl. J. Med. 2013, 369, 840–851. [Google Scholar] [CrossRef]
  24. Thamphiwatana, S.; Angsantikul, P.; Escajadillo, T.; Zhang, Q.; Olson, J.; Luk, B.T.; Zhang, S.; Fang, R.H.; Gao, W.; Nizet, V.; et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. USA 2017, 114, 11488–11493. [Google Scholar] [CrossRef] [Green Version]
  25. Cirioni, O.; Giacometti, A.; Ghiselli, R.; Bergnach, C.; Orlando, F.; Silvestri, C.; Mocchegiani, F.; Licci, A.; Skerlavaj, B.; Rocchi, M.; et al. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 2006, 50, 1672–1679. [Google Scholar] [CrossRef] [Green Version]
  26. Mayeux, P.R. Pathobiology of lipopolysaccharide. J. Toxicol. Environ. Health 1997, 51, 415–435. [Google Scholar] [CrossRef] [PubMed]
  27. Cole, C.R.; Frem, J.C.; Schmotzer, B.; Gewirtz, A.T.; Meddings, J.B.; Gold, B.D.; Ziegler, T.R. The Rate of Bloodstream Infection Is High in Infants with Short Bowel Syndrome: Relationship with Small Bowel Bacterial Overgrowth, Enteral Feeding, and Inflammatory and Immune Responses. J. Pediatr. 2010, 156, 941–947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Shahunja, K.M.; Ahmed, T.; Hossain, M.I.; Islam, M.M.; Monjory, M.B.; Shahid, A.S.M.S.B.; Faruque, A.S.G.; Chisti, M.J. Clinical and laboratory characteristics of children under five hospitalized with diarrhea and bacteremia. PLoS ONE 2020, 15, e0243128. [Google Scholar] [CrossRef]
  29. Chen, S.; Liu, S.; Yuan, X.; Mai, H.; Lin, J.; Wen, F. Etiology, drug sensitivity profiles and clinical outcome of bloodstream infections: A retrospective study of 784 pediatric patients with hematological and neoplastic diseases. Pediatric Hematol. Oncol. 2019, 36, 482–493. [Google Scholar] [CrossRef] [PubMed]
  30. Galloway, D.P.; Troutt, M.L.; Kocoshis, S.A.; Gewirtz, A.T.; Ziegler, T.R.; Cole, C.R. Increased Anti-Flagellin and Anti-Lipopolysaccharide Immunoglobulins in Pediatric Intestinal Failure: Associations With Fever and Central Line-Associated Bloodstream Infections. JPEN. J. Parenter. Enteral Nutr. 2015, 39, 562–568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Kono, K.; Sekikawa, T.; Iizuka, H.; Ichihara, F.; Amemiya, H.; Ishikawa, T.; Matsumoto, Y. T-Cell Dysfunction in a Patient with Short Bowel Syndrome: Report of a Case. Surg. Today. 1999, 29, 1253–1256. [Google Scholar] [CrossRef]
  32. Kasten, K.R.; Tschöp, J.; Adediran, S.G.; Hildeman, D.A.; Caldwell, C.C. T cells are potent early mediators of the host response to sepsis. Shock 2010, 34, 327–336. [Google Scholar] [CrossRef]
  33. Steinhagen, F.; Schmidt, S.V.; Schewe, J.C.; Peukert, K.; Klinman, D.M.; Bode, C. Immunotherapy in sepsis—Brake or accelerate? Pharmacol. Ther. 2020, 208, 107476. [Google Scholar] [CrossRef] [PubMed]
  34. Shankar-Hari, M.; Spencer, J.; Sewell, W.A.; Rowan, K.M.; Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis—Biological plausibility from a critical care perspective. Crit. Care 2011, 16, 206. [Google Scholar] [CrossRef] [Green Version]
  35. Di Rosa, R.; Pietrosanti, M.; Luzi, G.; Salemi, S.; D’Amelio, R. Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis? Eur. J. Intern. Med. 2014, 25, 511–516. [Google Scholar] [CrossRef]
  36. Alejandria, M.M.; Lansang, M.A.D.; Dans, L.F.; Mantaring, J.B. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst. Rev. 2013, 2013, CD001090. [Google Scholar] [CrossRef]
  37. Almansa, R.; Tamayo, E.; Andaluz-Ojeda, D.; Nogales, L.; Blanco, J.; Eiros, M.M.; Gomez-Herreras, J.I.; Bermejo-Martin, J.F. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit. Care 2015, 19, 90. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Zeng, M.Y.; Cisalpino, D.; Varadarajan, S.; Hellman, J.; Warren, H.S.; Cascalho, M.; Inohara, N.; Núñez, G. Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. Immunity 2016, 44, 647–658. [Google Scholar] [CrossRef] [Green Version]
  39. Speer, E.M.; Diago-Navarro, E.; Ozog, L.S.; Raheel, M.; Levy, O.; Fries, B.C. A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues. Front. Immunol. 2020, 11, 2249. [Google Scholar] [CrossRef] [PubMed]
  40. Maric, S.; Flüchter, P.; Guglielmetti, L.C.; Staerkle, R.F.; Sasse, T.; Restin, T.; Schneider, C.; Holland-Cunz, S.G.; Crenn, P.; Vuille-Dit-Bille, R.N. Plasma citrulline correlates with basolateral amino acid transporter LAT4 expression in human small intestine. Clin. Nutr. 2021, 40, 2244–2251. [Google Scholar] [CrossRef] [PubMed]
  41. Pabisek-Miernik, J.; Kościelniak-Merak, B.; Sporadyk, M.; Tomasik, P.J. Ghrelin, visfatin and irisin in children with short bowel syndrome. Folia Med. Cracov. 2019, 59, 5–14. [Google Scholar] [CrossRef] [PubMed]
  42. Turato, W.M.; Sales-Campos, H.; Braga, C.B.M.; Cunha, S.F.C.; Silvah, J.H.; da Silva, J.S.; Marchini, J.S.; de Barros Cardoso, C.R. The impact of intestinal resection on the immune function of short bowel syndrome patients. Hum. Immunol. 2016, 77, 1202–1208. [Google Scholar] [CrossRef] [PubMed]
  43. Metin, M.; Altun, A.; Köylüoğlu, G. The effect of probiotics on ıntestinal motility in an experimental short bowel model. Acta Cir. Bras. 2020, 35, 1–14. [Google Scholar] [CrossRef]
  44. Santacroce, L.; Man, A.; Charitos, I.A.; Haxhirexha, K.; Topi, S. Current knowledge about the connection between health status and gut microbiota from birth to elderly. A narrative review. Front. Biosci. 2021, 26, 135. [Google Scholar] [CrossRef]
  45. Ballini, A.; Gnoni, A.; De Vito, D.; Dipalma, G.; Cantore, S.; Gargiulo Isacco, C.; Saini, R.; Santacroce, L.; Topi, S.; Scarano, A.; et al. Effect of probiotics on the occurrence of nutrition absorption capacities in healthy children: A randomized double-blinded placebo-controlled pilot study. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 8645–8657. [Google Scholar] [CrossRef] [PubMed]
  46. Asha, M.Z.; Khalil, S.F.H. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020, 20, e13–e24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Pathogens 10 01021 g001 550
Figure 1. LPS neutralization in vitro. E. coli LPS was incubated with mouse splenocytes plus 5% (A,B), 10% (C,D) or 20% (E,F) concentration of plasma from SBS or HC subjects. TNF-α and IL-6 from culture supernatants were quantified by a solid-phase sandwich ELISA performed in duplicate or triplicate wells. (A,B): Pro-inflammatory cytokine inhibition by 5% plasma. (C,D): Pro-inflammatory cytokine inhibition by 10% plasma. (E,F): Pro-inflammatory cytokine inhibition by 20% plasma. Data are presented as median, and each datapoint represents one subject. A non-parametric Mann–Whitney T-test was applied to analyze the significant difference. * p < 0.05. SBS: short bowel syndrome, HC: healthy controls.
Figure 1. LPS neutralization in vitro. E. coli LPS was incubated with mouse splenocytes plus 5% (A,B), 10% (C,D) or 20% (E,F) concentration of plasma from SBS or HC subjects. TNF-α and IL-6 from culture supernatants were quantified by a solid-phase sandwich ELISA performed in duplicate or triplicate wells. (A,B): Pro-inflammatory cytokine inhibition by 5% plasma. (C,D): Pro-inflammatory cytokine inhibition by 10% plasma. (E,F): Pro-inflammatory cytokine inhibition by 20% plasma. Data are presented as median, and each datapoint represents one subject. A non-parametric Mann–Whitney T-test was applied to analyze the significant difference. * p < 0.05. SBS: short bowel syndrome, HC: healthy controls.
Pathogens 10 01021 g001
Pathogens 10 01021 g002 550
Figure 2. Anti-inflammatory effect of plasma from SBS or HC subjects in E. coli-stimulated splenocyte cultures. E. coli strains ATCC 25922 (A,D), K1 RS218 (B,E), and O86:B1 (C,F) were incubated with mouse splenocytes plus 20% plasma from either SBS or HC subjects. TNF-α and IL-6 in culture supernatants were quantified by ELISA, performed in either duplicate or triplicate wells. Data are presented as median, and each datapoint represents one subject. A non-parametric Mann–Whitney T-test was applied to analyze the statistical significance. * p < 0.05. SBS; short bowel syndrome, HC; healthy controls.
Figure 2. Anti-inflammatory effect of plasma from SBS or HC subjects in E. coli-stimulated splenocyte cultures. E. coli strains ATCC 25922 (A,D), K1 RS218 (B,E), and O86:B1 (C,F) were incubated with mouse splenocytes plus 20% plasma from either SBS or HC subjects. TNF-α and IL-6 in culture supernatants were quantified by ELISA, performed in either duplicate or triplicate wells. Data are presented as median, and each datapoint represents one subject. A non-parametric Mann–Whitney T-test was applied to analyze the statistical significance. * p < 0.05. SBS; short bowel syndrome, HC; healthy controls.
Pathogens 10 01021 g002
Pathogens 10 01021 g003 550
Figure 3. Anti-inflammatory effect of plasma from SBS and HC subjects on E. coli sepsis. Mice administered intravenously with PBS, SBS plasma or HC plasma were challenged 16 h later with an LD100 dose (5 × 107 CFU) of E. coli ATCC 25922 strain intraperitoneally. Blood from each mouse was collected 22 h later and TNF-α and IL-6 levels in plasma were determined by ELISA. Data are presented as median with each data point representing one mouse. Non-parametric Mann-Whitney T-test was applied to analyze the statistical significance. * p < 0.05, ** p <0.001. SBS; short bowel syndrome, HC; healthy controls.
Figure 3. Anti-inflammatory effect of plasma from SBS and HC subjects on E. coli sepsis. Mice administered intravenously with PBS, SBS plasma or HC plasma were challenged 16 h later with an LD100 dose (5 × 107 CFU) of E. coli ATCC 25922 strain intraperitoneally. Blood from each mouse was collected 22 h later and TNF-α and IL-6 levels in plasma were determined by ELISA. Data are presented as median with each data point representing one mouse. Non-parametric Mann-Whitney T-test was applied to analyze the statistical significance. * p < 0.05, ** p <0.001. SBS; short bowel syndrome, HC; healthy controls.
Pathogens 10 01021 g003
Pathogens 10 01021 g004 550
Figure 4. Effect of plasma from SBS and HC subjects on E. coli sepsis-induced mortality. Mice were treated intravenously with PBS, SBS plasma or HC plasma and, 16 h later, intraperitoneally challenged with LD100 E. coli ATCC 25922 strain. Post-challenge, mortality over 6 days was recorded, and survival distribution among the groups was determined using a log-rank Mantel–Cox test (A,B). Body weight was monitored daily and presented as mean ± SD (C). dpc: days post-challenge. * p < 0.05. ** p < 0.01. SBS: short bowel syndrome, HC: healthy controls.
Figure 4. Effect of plasma from SBS and HC subjects on E. coli sepsis-induced mortality. Mice were treated intravenously with PBS, SBS plasma or HC plasma and, 16 h later, intraperitoneally challenged with LD100 E. coli ATCC 25922 strain. Post-challenge, mortality over 6 days was recorded, and survival distribution among the groups was determined using a log-rank Mantel–Cox test (A,B). Body weight was monitored daily and presented as mean ± SD (C). dpc: days post-challenge. * p < 0.05. ** p < 0.01. SBS: short bowel syndrome, HC: healthy controls.
Pathogens 10 01021 g004
Table
Table 1. Demographics and characteristics of subjects with SG.
Table 1. Demographics and characteristics of subjects with SG.
CharacteristicsSubject 1Subject 2Subject 3Subject 4
Age (years)59149
Sex FMFF
DiagnosisMalrotation, Midgut volvulus, Jejunal atresiaNecrotizing enterocolitis, Jejunal perforationsLarge and small bowel atresia, Persistent omphalovitelline ductGastroschisis
Remaining Small Bowel LengthUnknown. Noted to have resection of 3 cm jejunum, 6 cm ileum63.6 cm41 cm45 cm
PN a dependence 9%14%72%100%
Current Central Line (Duration)Broviac (59 months)Port-a-Cath (12 months) Broviac (13 months)Broviac (39 months)
Number of Line Infections b02121
Time Since Last CLABSI, past organisms IsolatedNA8 years Lactobacillus7 years corynebacterium spp1 month E. coli, K.oxytoca, S.epidermidis, S.haemolyticus, S. hominis, S.gallolyticus, E. faecalis
Antibiotic Therapy for SIBO c or Prokinetic Effects YesYesYesNo
Days from Last Antibiotic Exposure7146035
a Parenteral Nutrition. b Confirmed within our institution. Subjects 3 and 4 received prior care at outside facilities. Subject 3 was reported to have multiple line infections of a previously unknown number. c Small Intestinal Bacterial Overgrowth.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hajam, I.A.; Ali, F.; Young, J.; Garcia, M.A.; Cannavino, C.; Ramchandar, N.; Liu, G.Y. Anti-Inflammatory Properties of Plasma from Children with Short Bowel Syndrome. Pathogens 2021, 10, 1021. https://doi.org/10.3390/pathogens10081021

AMA Style

Hajam IA, Ali F, Young J, Garcia MA, Cannavino C, Ramchandar N, Liu GY. Anti-Inflammatory Properties of Plasma from Children with Short Bowel Syndrome. Pathogens. 2021; 10(8):1021. https://doi.org/10.3390/pathogens10081021

Chicago/Turabian Style

Hajam, Irshad Ahmed, Farhana Ali, Jocelyn Young, Mary Abigail Garcia, Christopher Cannavino, Nanda Ramchandar, and George Y. Liu. 2021. "Anti-Inflammatory Properties of Plasma from Children with Short Bowel Syndrome" Pathogens 10, no. 8: 1021. https://doi.org/10.3390/pathogens10081021

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop